CG Oncology (CGON) Change in Accured Expenses (2023 - 2026)

CG Oncology (CGON) has 4 years of Change in Accured Expenses data on file, last reported at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 92.22% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $9.4 million (down 9.63% YoY), and the FY2025 full-year result was $8.7 million, up 58.28% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $1.6 million, down from $3.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $7.5 million in Q2 2025 and bottomed at -$4.1 million in Q1 2024.
• The 4-year median for Change in Accured Expenses is $1.6 million (2026), against an average of $1.5 million.
• The widest annual swing landed in 2024, when Change in Accured Expenses slumped 2712.03%; it then soared 263.53% in 2025.
• A 4-year view of Change in Accured Expenses shows it stood at $1.8 million in 2023, then surged by 89.98% to $3.3 million in 2024, then gained by 11.77% to $3.7 million in 2025, then tumbled by 56.93% to $1.6 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.6 million (Q1 2026), $3.7 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.

Peer Comparison